We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The companies have partnered to discover, develop and commercialise in-vivo engineered Chimeric Antigen Receptor Monocyte (CAR-M) therapeutics for the treatment of cancer.
Carisma Therapeutics announced the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for the Company's lead product candidate, CT-0508.